VFA
CORT icon

Virtus Fund Advisers’s Corcept Therapeutics CORT Stock Holding History

Virtus Fund Advisers’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-4,553
Closed -$13K – 1314
2014
Q2 		$13K Buy
+4,553
New +$13.4K ﹤0.01% 2664

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
CCA
Catalyst Capital Advisors Huntington, New York $6.03B AUM 24.5% 1-Year Est. Return

Virtus Fund Advisers's CORT Position: Q3 2014 in Review

Virtus Fund Advisers sold out of Corcept Therapeutics (CORT) in Q3 2014, closing a stake of 4,553 shares — an estimated $13K sold.

Virtus Fund Advisers first reported a position in CORT in Q2 2014 and held it in 1 quarter. The position peaked at $13K in Q2 2014. 55 funds tracked by Wall St. Rank hold CORT as of Q3 2014.

  • Virtus Fund Advisers reported no remaining Corcept Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 4,553 Corcept Therapeutics shares in Q3 2014, an estimated $13K.
  • Virtus Fund Advisers first reported a position in Corcept Therapeutics in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's Corcept Therapeutics position peaked at $13K in Q2 2014.
  • 55 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.